Tyra Biosciences Announces Preclinical Proof-Of-Concept Results With TYRA-300; Demonstrates Increases In Long Bone Length And Binding Against HCH Altered Protein; Remains On Track To Submit ACH Investigational New Drug Application In 2H24
Portfolio Pulse from Benzinga Newsdesk
Tyra Biosciences has announced preclinical proof-of-concept results for TYRA-300, showing increased long bone length and effective binding against HCH altered protein. The company is on track to submit an ACH Investigational New Drug Application in the second half of 2024.
July 02, 2024 | 8:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tyra Biosciences has reported promising preclinical results for TYRA-300, demonstrating increased long bone length and effective binding against HCH altered protein. The company plans to submit an ACH Investigational New Drug Application in the second half of 2024.
The positive preclinical results for TYRA-300 and the planned submission of an Investigational New Drug Application are likely to boost investor confidence and positively impact Tyra Biosciences' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100